Tarsus Pharmaceuticals Inc. (TARS)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Tarsus Pharmaceuticals: XDEMVY Now Pays The Bills, And The Retina Deals Work Like Options
Tarsus Pharmaceuticals is transitioning from a single-product launch story to a cash-generating eye care platform, with XDEMVY now funding the business. TARS raised XDEMVY 2026 net sales guidance to $685–$705 million, with gross margins in the low 90s and positive operating cash flow of $37 million in H1 2026. Recent retina acquisitions (iRenix, and Alkeus) are milestone-heavy, minimizing upfront risk and leveraging a targeted commercial infrastructure for future launches.
Tarsus Pharmaceuticals Q2 Earnings Call Highlights
Tarsus Pharmaceuticals NASDAQ: TARS reported second-quarter growth in sales of its Demodex blepharitis treatment XDEMVY and announced a pending acquisition of Alkeus Pharmaceuticals, adding late-stage investigational Stargardt disease therapy gildeuretinol, also known as ALK-001, to its pipeline.
Tarsus Pharmaceuticals, Inc. (TARS) Q2 2026 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (TARS) Q2 2026 Earnings Call Transcript
Tarsus Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 72 | $3,359.61 | $5,085.16 | $1,725.55 | 51.36% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 79,888 | $5.03M | $5.63M | $599,140.72 | 11.92% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 29,316 | $1.68M | $2.07M | $390,192.71 | 23.27% |
| BG Bart Gancher Intech Investment Management LLC | 9,677 | $488,846.59 | $698,485.86 | $209,639.27 | 42.88% |
| KT Kevin Tang Tang Capital Management LLC | 1.19M | $27.25M | $83.59M | $56.34M | 206.75% |
Tarsus Pharmaceuticals Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| FB Francois Brisebois Oppenheimer | 1,556.29 | $108,963.76 | $108,387.94 | -$575.82 | -0.53% |
Tarsus Pharmaceuticals Inc. (TARS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Tarsus Pharmaceuticals Inc. ever had a stock split?
Tarsus Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Bobak R. Azamian CEO | NASDAQ (NGS) Exchange | 87650L103 CUSIP |
| US Country | 370 Employees | - Last Dividend | - Last Split | 16 Oct 2020 IPO Date |
Overview
Tarsus Pharmaceuticals, Inc. is a pioneering figure in the biopharmaceutical domain, primarily targeting the eye care segment. Since its establishment in 2016, the company has embarked on a journey to innovate within the United States, focusing on the development and commercialization of novel therapeutic candidates. Headquartered in Irvine, California, Tarsus Pharmaceuticals stands out for its dedication to addressing some of the most challenging conditions affecting eye health today. The company's strategic approach encompasses the tackling of diseases through the advancement of unique therapeutic solutions, with an emphasis on both treatment efficacy and patient comfort.
Products and Services
- XDEMVY: This flagship product candidate by Tarsus Pharmaceuticals represents a significant breakthrough in the treatment of blepharitis resulting from Demodex mite infestation. In addition, XDEMVY shows promise for treating meibomian gland disease, showcasing the company's ability to address complex eye conditions with innovative solutions. Through rigorous development, XDEMVY aims to alleviate the discomfort and visual impairment caused by these conditions, offering hope to sufferers seeking effective treatments.
- TP-04: Targeted at the treatment of rosacea, TP-04 embodies Tarsus Pharmaceuticals' commitment to expanding its portfolio into dermatological conditions linked to eye health. By focusing on this common but often challenging-to-treat skin condition, TP-04 signifies the company’s dedication to leveraging its expertise beyond conventional eye care and into related areas of patient need.
- TP-05: A testament to the company's innovative approach towards infectious disease prevention, TP-05 is in development for Lyme prophylaxis and community malaria reduction. This initiative reflects Tarsus Pharmaceuticals' broader vision of impacting global health by tackling diseases that have substantial community-wide effects, thus evidencing a commitment to public health and prevention beyond the realm of eye care.
- Lotilaner: With its development of lotilaner, Tarsus Pharmaceuticals is venturing into new therapeutic categories, applying its expertise to tackle diseases in human medicine across eye care, dermatology, and infectious disease prevention. This effort underlines the company’s versatility and willingness to explore the potential of its discoveries in diverse medical fields, thereby broadening the scope of its impact on patient health and wellbeing.
Contact Information
